Table 1 Case series summary of surgical treatment of TAAAD complicated with CM

Okita et al. [12]

RS

2021

50

13.1

68.1 ± 9.2

NA

14 (28%)

Stroke 8

5-year survival (75.2 ± 12.5%)

10-year survival (60.5 ± 23.4%)

Sugiyama et al. [13]

RS

2021

19

21

69 (39–84)

2

2 (10.5%)

Extensive cerebral infarction

NA

Gomibuchi et al. [14]

RS

2021

42

21.3

64.9 ± 11.1

22

2 (4.8%)

NA

NA

Sasaki et al. [8]

RS

2020

9

7.1

66.2 ± 12.9

8

0

0

24 (all survival)

Shimura et al. [15]

RS

2020

16

7.7

63 (32–83)

8

1 (6.3%)

Severe cerebral edema

101 ± 7

Luehr et al. [16]

RS

2016

23

6.5

66.3 (55.2–69.9)

5

3 (13.0%)

Cerebral haemorrhag 2, MOF 1

15.2 (4.8–34.1)

Di Eusanio et al. [3]

RS

2013

99

7.5

63.1 ± 13.7 62.8 ± 12.2

NA

33 (33.3%)

NA

Median 36

5-year survival: 67.1% (CVA), 57.1% (coma)

Morimoto et al. [5]

RS

2011

41

26.1

67.3 ± 10.0, 69.7 ± 11.5

16

6 (14.6%)

Large hemispheric infarction

57.6 (1.2–136.8)

5-year survival 65% ± 8%

10-year survival 59% ± 9%

Nakamura [17]

RS

2011

10

22.4

69 ± 9 (57–84)

5

0

0

18 ± 5

Tsukube et al. [18]

RS

2011

24

14.9

71.9 (44–91)

18

4 (16.7%)

Aortic rupture 1, AMI 1, massive brain edema 2

34.5 ± 25.1

3 years cumulative survival rate 71.8%

Estrera et al. [9]

RS

2006

14

19

56 (43–73)

6

1 (7%)

Small bowel necrosis

18.5

1-year survival 81.3%

5-year survival 58.0%

Tanaka et al. [19]

RS

2005

16

25.3

71.6 ± 7.7

10

7 (43.7%)

Severe brain damage

25.2 ± 21 (2–56)

4-year survival 50.1%

Total

RS

2005–2021

363 (15.5%)

15.9

65.7 ± 13 (32–91)

100

73 (20.1%)

Neurological damage (n = 28), MOF (n = 1), aortic rupture (n = 1), AMI (n = 1), small bowel necrosis (n = 1)

40.1 ± 37.6

5 years survival 65.3 ± 11%